ZD 5522
Alternative Names: ICI D 5522Latest Information Update: 07 Apr 1999
At a glance
- Originator AstraZeneca
- Class Antihyperglycaemics
- Mechanism of Action Aldehyde reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 14 Sep 1998 Discontinued-Preclinical for Diabetic neuropathies in United Kingdom (Unknown route)
- 12 Dec 1997 Preclinical development for Diabetic neuropathies in United Kingdom (Unknown route)